iZafe Group
12.10.2021 09:01:48 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 12, 2021 / iZafe Group (STO:IZAFE-B)
iZafe Group AB (publ) ("iZafe" or "the Company") announces that Vice Chairman of the Board Göran Hermansson and CEO Anders Segerström are subscribing for an additional of combined 458,000 units in the ongoing rights issue of units (" The Rights Issue"), which was announced and communicated through press release on September 6, 2021. An EU-growth prospect containing the full terms for the Rights Issue was announced and communicated through press release on September 24, 2021.
Today, the Company announces that Göran Hermansson and Anders Segerström will subscribe for a total of 458,000 units, corresponding to SEK 687,000.00 SEK. Göran Hermansson subscribes for 324,667 units, corresponding to SEK 487,000.50. Anders Segerström subscribes for 133,333 units, corresponding to SEK 199,999.50, in addition to his existing subscription commitment of SEK 315,046.50. Anders Segerström has received unit rights from Göran Hermansson in order to subscribe with preferential rights. This means that the Board of Directors and management have subscribed for a total of 876,149 units, corresponding to SEK 1,314,223.50 in the ongoing Rights Issue.
Subscription commitment and underwriting commitments
The Rights Issue is already covered to approximately 18 percent through subscription commitments and to approximately 82 percent through underwriting commitments. In total, 100 percent of the Rights Issue is thus covered by subscription commitments and underwriting commitments before Anders Segerström and Göran Hermansson's additional subscriptions.
The subscription commitments have been made by a number of existing shareholders in the Company (by, among others, Chairman of the Board Joachim Källsholm, Board member Richard Wolff, CEO Anders Segerström, CFO Ida Almgren, Sales Manager Tobias Johansson, former Chairman of the Board Carl Johan Merner and the Company's founders Göran Sjönell and Sten Röing) as well as external investors.
Important dates for the Rights Issue
Trading in unit rights on Nasdaq First North Premier Growth Market: October 4 - October 13, 2021
Subscription period for the Rights Issue: October 4 - October 18, 2021
Estimated date for publication of issue results: October 21, 2021
Advisors
Mangold Fondkommission AB is the financial advisor to iZafe in connection with the Rights Issue. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the Rights Issue.
Contacts
Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm
E-mail: ir@izafegroup.com
www.izafe.se/investor-relations/
About Us
iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.
The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se . Further information is available at www.izafe.se/investor-relations/ .
Attachments
Board member and the CEO of iZafe subscribe for an additional 458,000 units in ongoing rights issue
SOURCE: iZafe Group
View source version on accesswire.com:
https://www.accesswire.com/667692/Board-Member-and-The-CEO-of-iZafe-Subscribe-for-an-Additional-458000-Units-in-Ongoing-Rights-Issue
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release
BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.
Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release
CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release
PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning
OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release
MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
